Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
United Kingdom (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Purified NA/LE Rat Anti-Mouse CD279 (PD-1)
      Purified NA/LE Rat Anti-Mouse CD279 (PD-1)
      Flow cytometric analysis of recombinant Mouse PD-1 Ligand 2-Human IgG1 Fc Chimera Protein (PD-L2 Fc) binding blockade by Purified NA/LE Rat Anti-Mouse CD279 (PD-1) antibody on activated mouse leucocytes. C57BL/6 mouse splenic leucocytes were cultured (3 days, 37°C) with plate-bound Purified NA/LE Hamster Anti-Mouse CD3 antibody (Cat. No. 553057).        The activated leucocytes were either not stained (Histogram 4; Secondary Antibody Control) or stained with Recombinant Mouse PD-L2/B7-DC (Human IgG1) Fc Chimera Protein (PD-L2 Fc; R&D Systems Cat. No. 1022-PL-100; Histogram 3) at 1 µg/test to assess PD-L2 Fc binding levels. For experimental controls, activated leucocytes preincubated with either Purified NA/LE Rat IgG2a Isotype Control (20 µg/test; Cat. No. 554687; Histogram 2) or Purified NA/LE Rat Anti-Mouse CD279 (PD-1) antibody (20 µg/test; Cat. No. 568262; Histogram 1) were also assessed prior to staining with the PD-L2 Fc protein. The cells were washed and secondarily stained with R-Phycoerythrin AffiniPure Goat Anti-Human IgG, Fc fragment specific (PE Anti-Human IgG Fc; Jackson ImmunoResearch, Cat. No. 109-115-098). DAPI Solution (Cat. No. 564907) was added to cells right before analysis.        The fluorescence histograms showing the bound levels of PD-L2 Fc protein were derived from gated events with the forward and side light-scatter characteristics of viable (DAPI-negative) activated leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
      Purified NA/LE Rat Anti-Mouse CD279 (PD-1)
      Flow cytometric analysis of recombinant Mouse PD-1 Ligand 2-Human IgG1 Fc Chimera Protein (PD-L2 Fc) binding blockade by Purified NA/LE Rat Anti-Mouse CD279 (PD-1) antibody on activated mouse leucocytes. C57BL/6 mouse splenic leucocytes were cultured (3 days, 37°C) with plate-bound Purified NA/LE Hamster Anti-Mouse CD3 antibody (Cat. No. 553057).        The activated leucocytes were either not stained (Histogram 4; Secondary Antibody Control) or stained with Recombinant Mouse PD-L2/B7-DC (Human IgG1) Fc Chimera Protein (PD-L2 Fc; R&D Systems Cat. No. 1022-PL-100; Histogram 3) at 1 µg/test to assess PD-L2 Fc binding levels. For experimental controls, activated leucocytes preincubated with either Purified NA/LE Rat IgG2a Isotype Control (20 µg/test; Cat. No. 554687; Histogram 2) or Purified NA/LE Rat Anti-Mouse CD279 (PD-1) antibody (20 µg/test; Cat. No. 568262; Histogram 1) were also assessed prior to staining with the PD-L2 Fc protein. The cells were washed and secondarily stained with R-Phycoerythrin AffiniPure Goat Anti-Human IgG, Fc fragment specific (PE Anti-Human IgG Fc; Jackson ImmunoResearch, Cat. No. 109-115-098). DAPI Solution (Cat. No. 564907) was added to cells right before analysis.        The fluorescence histograms showing the bound levels of PD-L2 Fc protein were derived from gated events with the forward and side light-scatter characteristics of viable (DAPI-negative) activated leucocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
      Product Details
      Down Arrow Up Arrow


      BD Pharmingen™
      PD-1; Pdc1; Pdcd1; mPD-1; programmed cell death 1 protein
      Mouse (QC Testing)
      Rat IgG2a, κ
      PD-1 cDNA and PD-1-Ig Fusion Protein
      Blocking, Flow cytometry (Tested During Development)
      1.0 mg/ml
      No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
      RUO


      Preparation And Storage

      Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      2. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      3. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      4. An isotype control should be used at the same concentration as the antibody of interest.
      Show More blue down arrow Show Less blue up arrow
      568262 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      29F.1A12

      The 29F.1A12 monoclonal antibody specifically recognizes CD279 which is also known as Programmed Death-1 (PD-1). CD279 (PD-1) is a ~55-kDa type I transmembrane glycoprotein that is encoded by Pdcd1 (Programmed cell death 1) which belongs to the CD28/CTLA-4 family of immunoreceptors within the Ig superfamily. CD279 (PD-1) is comprised of an extracellular region with an IgV-like domain, a transmembrane sequence, and an intracellular region with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) that are associated with suppressive immunoregulatory functions. CD279 (PD-1) is variably expressed on some thymocyte subsets and developing B lymphocytes at the pro-B-cell stage. It is also inducibly expressed on activated myeloid cells, B cells, and T cells including exhausted T cells found in mice during chronic viral infections or cancer. Although this co-inhibitory receptor plays roles in mediating immunological tolerance and preventing autoimmune responses it can also inhibit protective immune responses against microbial infections and cancer. CD273 (also known as PD-L2 or B7-DC) and CD274 (PD-L1 or B7-H1) are members of the B7 family within the Ig superfamily. These molecules serve as ligands for CD279 (PD-1) and are variably expressed on lymphoid and nonlymphoid cell types including antigen-presenting cells and tumor cells. The 29F.1A12 antibody can reportedly block the binding of these ligands as well as other mouse PD-1-specific antibodies including clones J43, G4, and RMP1-14. Antibody-mediated inhibition of the interaction between PD-1 and its ligands can serve as an immune checkpoint blockade that can augment T-cell responses against tumor cells.

      568262 Rev. 1
      Format Details
      Down Arrow Up Arrow
      NA/LE
      NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
      NA/LE
      568262 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "568262" on CiteAb

      Development References (4)

      1. Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.. Eur J Immunol. 2003; 33(10):2706-16. (Immunogen: Flow cytometry, Immunofluorescence, Immunohistochemistry). View Reference
      2. Lázár-Molnár E, Gácser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD. The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum.. Proc Natl Acad Sci U S A. 2008; 105(7):2658-63. (Clone-specific: In vivo exacerbation). View Reference
      3. Polesso F, Munks MW, Rott KH, Smart S, Hill AB, Moran AE. PD-1-specific "Blocking" antibodies that deplete PD-1+ T cells present an inconvenient variable in preclinical immunotherapy experiments.. Eur J Immunol. 2021; 51(6):1473-1481. (Clone-specific). View Reference
      4. Puzey MS, Craig CJ. Hydrometrocolpos--a case report.. S Afr Med J. 1992; 81(6):336-7. (Biology). View Reference
      View All (4) View Less
      568262 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.